Solid Tumours
Conditions
Brief summary
WAYFIND-R is a registry that aims to capture high-quality real-world data linking next-generation sequencing, treatments and outcomes from cancer patients diagnosed with a solid tumour. The WAYFIND-R has three main overarching objectives: 1. To provide a platform to support the design and conduct of clinical and epidemiological research; 2. To develop an evidence-generation platform to better understand health outcomes and cancer care processes; and 3. To characterize the treatments and clinical course of solid tumor cancers in patients who have undergone NGS testing.
Interventions
None listed
Sponsors
Hoffmann-La Roche
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participant is an adult (according to the age of majority as defined by local regulations) * Participant is currently diagnosed with any type of solid tumour cancer, at any stage of the disease, at the enrollment date (informed consent date) * Participant has undergone NGS testing, no longer than 3 months prior to the enrollment date, irrespective of the availability of test results * Informed consent has been obtained from the participant or legally authorized representative, as per local regulations
Exclusion criteria
-Participant has a prior or current diagnosis of haematological malignancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival | From date of registry entry until death, for up to 5 years |
Countries
Argentina, Austria, Brazil, Canada, Chile, Colombia, Egypt, Estonia, France, Germany, Greece, Hungary, India, Ireland, Israel, Lebanon, Mexico, Philippines, Poland, Portugal, Saudi Arabia, Serbia, Slovakia, Slovenia, South Africa, Spain, Taiwan, Thailand, Turkey (Türkiye), United Arab Emirates, United Kingdom, Vietnam
Contacts
STUDY_DIRECTORClinical Trials
Hoffmann-La Roche
Outcome results
None listed